J3260Tobramycin sulfate injection
Published CMS Medicare Part B payment-limit context for J3260, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$2.186
per 80 MG · Medicare Part B
Up 8.3%from $2.019 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$2.5811$1.4739
2024-Q4: $2.27; 2025-Q1: $1.966; 2025-Q2: $1.595; 2025-Q3: $2.46; 2025-Q4: $2.373; 2026-Q1: $2.071; 2026-Q2: $2.019; 2026-Q3: $2.186
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Tobramycin ingredient family (FDA data as of August 20, 2026).
Tobramycin Sulfate
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Tobramycin presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J7682 | Tobramycin non-comp unit | $12.305 per 300 MG | $7.766 per 300 MG | Up 58.4% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.